FDA’s 2026 Tauklarify Tau PET Imaging Approval: What People With Mild Cognitive Impairment Should Know About the News
Learn how the new tau PET scan clarifies MCI evaluation, its accuracy, limits, and questions to ask your doctor.
Category Alzheimer’s
Day-One Subcutaneous Leqembi for Early Alzheimer’s in 2026: Questions People With Mild Cognitive Impairment Can Ask an Alzheimer’s Specialist
Learn which eligibility, dosing, safety, and coverage questions to bring to your Alzheimer's specialist visit.
How 2026 Tau Imaging News May Affect Alzheimer’s Workups: Questions People With Mild Cognitive Impairment Can Bring to a Clinician
Ask your clinician whether tau PET, blood testing, or both fit your MCI workup, safety needs, and next steps.
Tauklarify Tau PET vs Alzheimer’s Blood Tests in 2026: Questions People With Mild Cognitive Impairment Can Bring to a Clinician
Learn what tau PET and blood tests show and which follow-up questions clarify diagnosis and next steps for MCI.
Tauklarify Tau PET vs Amyloid PET After the 2026 Approval: Questions People With Mild Cognitive Impairment Can Bring to a Clinician
Compare tau and amyloid PET and bring clear staging and treatment questions to your next memory-clinic visit.
Tauklarify Imaging for Alzheimer’s Tau Tangles in 2026: Questions People With Mild Cognitive Impairment Can Bring to a Clinician
Bring focused questions about tau results, next steps, and scan safety to your next memory-clinic visit.
FDA’s 2026 Tauklarify Tau PET Imaging Approval: Questions People With Mild Cognitive Impairment Can Bring to a Clinician
Bring clear questions on tau results, amyloid status, and scan-day steps to your next memory-clinic visit.
PrecivityAD2 and Younger-Onset Alzheimer’s Diagnosis in 2026: Questions People With Mild Cognitive Impairment Can Bring to a Clinician
Learn what PrecivityAD2 measures, what scores mean, and which follow-up questions clarify a diagnosis under age 65.
The Third FDA-Cleared Alzheimer’s Blood Biomarker Test in 2026: Questions People With Mild Cognitive Impairment Can Bring to a Clinician
Learn what the new PrecivityAD2 blood test shows and which questions to bring to your clinic visit.
PrecivityAD2 as an Adjunct to a 2026 Alzheimer’s Assessment: Questions People With Mild Cognitive Impairment Can Bring to a Clinician
Learn which eligibility, accuracy, and follow-up questions help people with MCI use PrecivityAD2 results with a clinician.